AbbVie sees a chance to upset Gilead in the race to bring to market the first all-oral treatment for hepatitis C. Among the many drug-development races in pharma, few move as quickly as this contest.
Massachusetts' MC10 has developed a stretchable, sensor-laden technology you can wear, allowing for vital readings on the go, and with big-name backers like Medtronic and Reebok, the company believes its innovation could revolutionize mobile health.
Within a year of its launch, North Carolina's NeuroTronik has closed a $13.1 million Series A to develop a device that treats heart failure with neuromodulation.
In a piece for Nature Biotechnology , serial biotech entrepreneur and MIT professor Robert Langer shared some of his experiences in launching more than two dozen biotechs over the past 26 years.
GlaxoSmithKline fired Jingwu Zang after allegations that the R&D shop he helmed in China published falsified data. Yet Zang has fired back in a report from The Wall Street Journal, saying that he played a supervisory role and had no part in the actual misrepresentations that appeared in a 2010 issue of Nature Medicine .
MPI Research is joining forces with inviCRO and 3D Imaging to open a state-of-the-art imaging center for drug discovery and development, pooling resources to create a one-stop shop.
The U.S. government has taken another big step forward in its campaign to end drug research projects involving chimps.
A new study asserts that the $14.5 billion federal tab for genomics research has paid off handsomely, with close to a trillion dollars in returns. But it didn't take long for the report to start attracting critics for the kind of math that was used by analysts at Battelle.
Celgene and most analysts have never met eye-to-eye on the future prospects of the psoriasis drug apremilast, which the biotech heavyweight expects could become a blockbuster seller. Yet at least one analyst argues that new data from a late-stage study of the oral treatment in patients with psoriatic arthritis could lift sales expectations for apremilast among his peers.
Once again, Amgen's R&D chief Sean Harper has Roger Perlmutter to thank for a positive late-stage outcome on one of the Big Biotech's top cancer prospects.